S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
LON:TILS

Tiziana Life Sciences (TILS) Share Forecast, Price & News

Compare
Today's Range
N/A
50-Day Range
58.50
▼
58.50
52-Week Range
N/A
Volume
297,127 shs
Average Volume
522,223 shs
Market Capitalization
£113.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsHeadlines

TILS stock logo

About Tiziana Life Sciences (LON:TILS) Stock

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. Its product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. The company also develops anti-IL6R (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients with severe respiratory symptoms. It has a collaboration agreement with FHI Clinical Inc. to conduct a phase 2 clinical trial for treating hospitalized severe COVID-19 patients with intranasal foralumab, a human anti-CD3 monoclonal antibody. The company was incorporated in 1998 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.


TILS Stock News Headlines

September 26, 2023 | uk.investing.com
Tiziana Life Sciences Ltd (0RP)
September 26, 2023 | tmcnet.com
Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis
September 27, 2023 | Stansberry Research (Ad)
Experts: NVIDIA Now "Too Big to Succeed"
Several of the market’s top analysts are sounding the alarm that NVIDIA’s share price may have reached its breaking point.
September 23, 2023 | americanbankingnews.com
Tiziana Life Sciences (LON:TILS) Stock Price Passes Below 200 Day Moving Average of $58.50
August 23, 2023 | technews.tmcnet.com
Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology
August 15, 2023 | msn.com
Tiziana Life Sciences’ stock soars 54% premarket after FDA clear path for trial of intranasal treatment for Alzheimer’s disease
April 21, 2023 | benzinga.com
Tiziana Life Sciences To Submit Alzheimer's IND In Q2 2023, Seeks $3 Million From An Alzheimer's Foundation To Support Phase 2a Trial
March 19, 2023 | seekingalpha.com
Tiziana Life Sciences CEO purchases shares
September 27, 2023 | Stansberry Research (Ad)
Experts: NVIDIA Now "Too Big to Succeed"
Several of the market’s top analysts are sounding the alarm that NVIDIA’s share price may have reached its breaking point.
September 25, 2022 | finanznachrichten.de
Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer
September 9, 2022 | benzinga.com
Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer
September 6, 2022 | yahoo.com
Harry Styles and Olivia Wilde Hit Their First Red Carpet Together Amid 'Don't Worry Darling' Drama
July 2, 2022 | proactiveinvestors.com
Tiziana Life Sciences' half-term report reveals it has made progress on all fronts
June 17, 2022 | finance.yahoo.com
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
June 9, 2022 | fool.co.uk
Tiziana Life Sciences
June 8, 2022 | benzinga.com
Proactive news headlines including NEO Battery Materials, New Age Metals, Belmont Resources, Ridgeline Minerals, Electra Battery Materials, Tiziana Life Sciences and Aben Resources
June 8, 2022 | benzinga.com
Tiziana Life Sciences Shares Jump After Multiple Sclerosis Data From Second Patient
June 7, 2022 | investing.com
Advan Co Ltd (7463)
May 21, 2022 | dailymail.co.uk
Silvio Berlusconi, 85, 'used women as sex slaves' at his infamous 'bunga bunga' parties during time as Italian PM and was a 'sultan in his own harem', court hears
April 5, 2022 | financialpost.com
Proactive news headlines including SPYR, Predictmedix, Bridgeline Digital, Tiziana Life Sciences, GameSquare and Empower Clinics
March 24, 2022 | proactiveinvestors.com
Tiziana Life Sciences: Multiple Sclerosis single study
March 24, 2022 | proactiveinvestors.com
Tiziana Life Sciences: Method of therapy delivery gives firm 'a novel market position'
January 28, 2022 | proactiveinvestors.com.au
2022 update: US listing and fresh data emerging
January 26, 2022 | lse.co.uk
MaxCyte expects improved full-year revenue on organic growth
January 10, 2022 | benzinga.com
Proactive news headlines including Starton Therapeutics, Safe-T Group, Genprex, Hawkmoon Resources, District Metals and Tiziana Life Sciences
October 28, 2021 | lse.co.uk
Tiziana Life Sciences Plc Share Chat
October 20, 2021 | apnews.com
Tiziana Life Sciences plc: Court Sanctions the Scheme of Arrangement and approves Reduction of ...
See More Headlines
Receive TILS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

TILS Company Calendar

Last Earnings
9/30/2020
Today
9/27/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:TILS
Previous Symbol
LON:ADI
CUSIP
N/A
CIK
N/A
Web
www.tizianalifesciences.com
Phone
+44-20-74952379
Fax
N/A
Employees
11
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
2.36
Current Ratio
6.54
Quick Ratio
6.41

Sales & Book Value

Annual Sales
£-3,595,000.00
Price / Sales
-31.67
Cash Flow
GBX 25.70 per share
Price / Cash Flow
2.28
Book Value
GBX 23.50 per share
Price / Book
2.49

Miscellaneous

Outstanding Shares
194,612,000
Free Float
N/A
Market Cap
£113.85 million
Optionable
Not Optionable
Beta
N/A
Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Gabriele Marco Antonio Cerrone M.B.A. (Age 49)
    MBA, Founder & Exec. Chairman
    Comp: $13.76M
  • Dr. Kunwar Shailubhai (Age 63)
    CEO, Chief Scientific Officer & Exec. Director
    Comp: $810k
  • Dr. Andrea Brancale
    Scientific Founder
  • Mr. Richard Clarkson Ph.D.
    Scientific Founder
  • Mr. Andrew Westwell Ph.D.
    Scientific Founder
  • Ms. Keeren Shah (Age 44)
    Fin. Director
  • Dr. Thomas H. Adams (Age 78)
    Head of Drug Devel. & Exec. Director
  • Dr. Neil Graham M.P.H. (Age 62)
    MBBS, M.D., MPH, Chief Medical Officer
  • Dr. Napoleone Ferrara (Age 63)
    Chairman of Scientific Advisory Board
  • Prof. Roberto Pellicciari
    Consultant

Key Competitors

View All Competitors













TILS Stock - Frequently Asked Questions

How have TILS shares performed in 2023?

Tiziana Life Sciences' stock was trading at GBX 58.50 at the beginning of the year. Since then, TILS shares have increased by 0.0% and is now trading at GBX 58.50.
View the best growth stocks for 2023 here.

How were Tiziana Life Sciences' earnings last quarter?

Tiziana Life Sciences PLC (LON:TILS) released its quarterly earnings data on Wednesday, September, 30th. The biotechnology company reported ($2.60) earnings per share for the quarter, topping analysts' consensus estimates of ($4.00) by $1.40.

What other stocks do shareholders of Tiziana Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tiziana Life Sciences investors own include Synergy Pharmaceuticals (SGYP), Micron Technology (MU), ServiceNow (NOW), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Broadcom (AVGO), Dropbox (DBX), Enterprise Products Partners (EPD) and Franco-Nevada (FNV).

What is Tiziana Life Sciences' stock symbol?

Tiziana Life Sciences trades on the London Stock Exchange (LON) under the ticker symbol "TILS."

How do I buy shares of Tiziana Life Sciences?

Shares of TILS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Tiziana Life Sciences' stock price today?

One share of TILS stock can currently be purchased for approximately GBX 58.50.

How much money does Tiziana Life Sciences make?

Tiziana Life Sciences (LON:TILS) has a market capitalization of £113.85 million and generates £-3,595,000.00 in revenue each year.

How can I contact Tiziana Life Sciences?

Tiziana Life Sciences' mailing address is 3rd Fl, 11-12 St. James's Square, LONDON, SW1Y 4LB, United Kingdom. The official website for the company is www.tizianalifesciences.com. The biotechnology company can be reached via phone at +44-20-74952379.

This page (LON:TILS) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -